TSHA

Taysha Gene Therapies, Inc.

A clinical-stage biotech developing gene therapies for rare nervous-system diseases. Founded in 2019 out of the University of Texas Southwestern Medical Center in Dallas, its lead program TSHA-102 is designed to treat the genetic root cause of Rett syndrome by delivering a single MECP2 gene directly into the spinal fluid. The company takes its name from the Caddo word "taysha," meaning "friend" or "ally" — the same word that gave Texas its name.

CUSIP: 877619106HealthcareUS1 holder

Ownership Activity Financials Filings

TSHA

TSHA

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Other Events